3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Benign Neoplasms in 19 studies
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "HIF-1 activity in tumors depends on availability of the HIF-1α subunit, the levels of which increase under hypoxic conditions and through activation of oncogenes and/or inactivation of tumor suppressor genes." | 2.48 | Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. ( Choi, HK; Lee, K; Xia, Y, 2012) |
| "Most solid tumors develop regions of hypoxia as they grow and outstrip their blood supply." | 2.46 | HIF-1alpha and cancer therapy. ( Koh, MY; Powis, G; Spivak-Kroizman, TR, 2010) |
| "Hep3B hepatoma, NCI-H87 stomach carcinoma, Caki-1 renal carcinoma, SiHa cervical carcinoma, and SK-N-MC neuroblastoma cells were grown as xenografts in immunodeficient mice (69 mice total)." | 1.32 | YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. ( Cho, YS; Chun, YS; Kim, J; Kim, MS; Lee, JC; Park, JW; Yeo, EJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Boovanahalli, SK | 1 |
| Jin, X | 1 |
| Jin, Y | 1 |
| Kim, JH | 1 |
| Dat, NT | 1 |
| Hong, YS | 1 |
| Lee, JH | 1 |
| Jung, SH | 1 |
| Lee, K | 2 |
| Lee, JJ | 1 |
| Xia, Y | 1 |
| Choi, HK | 1 |
| Yasuda, Y | 1 |
| Arakawa, T | 1 |
| Nawata, Y | 1 |
| Shimada, S | 1 |
| Oishi, S | 1 |
| Fujii, N | 1 |
| Nishimura, S | 1 |
| Hattori, A | 1 |
| Kakeya, H | 1 |
| Zhang, B | 1 |
| Huang, X | 1 |
| Wang, H | 1 |
| Gou, S | 1 |
| Harada, T | 1 |
| Hirose, K | 1 |
| Wada, Y | 1 |
| Sato, M | 1 |
| Ichise, K | 1 |
| Aoki, M | 1 |
| Kato, T | 1 |
| Takeda, K | 1 |
| Takai, Y | 1 |
| Liu, J | 1 |
| Yan, F | 1 |
| Chen, H | 1 |
| Wang, W | 1 |
| Liu, W | 1 |
| Hao, K | 1 |
| Wang, G | 1 |
| Zhou, F | 1 |
| Zhang, J | 1 |
| Subhani, S | 1 |
| Vavilala, DT | 1 |
| Mukherji, M | 1 |
| Harada, H | 1 |
| Itasaka, S | 1 |
| Zhu, Y | 1 |
| Zeng, L | 1 |
| Xie, X | 1 |
| Morinibu, A | 1 |
| Shinomiya, K | 1 |
| Hiraoka, M | 1 |
| Koh, MY | 1 |
| Spivak-Kroizman, TR | 1 |
| Powis, G | 1 |
| Chung, TH | 1 |
| Yen-Ping Kuo, M | 1 |
| Chen, JK | 1 |
| Huang, DM | 1 |
| Wilczynski, J | 1 |
| Duechler, M | 1 |
| Czyz, M | 1 |
| Pili, R | 1 |
| Donehower, RC | 1 |
| Yeo, EJ | 3 |
| Chun, YS | 3 |
| Cho, YS | 1 |
| Kim, J | 1 |
| Lee, JC | 1 |
| Kim, MS | 1 |
| Park, JW | 3 |
| Clottes, E | 1 |
| Pan, SL | 1 |
| Guh, JH | 1 |
| Peng, CY | 1 |
| Wang, SW | 1 |
| Chang, YL | 1 |
| Cheng, FC | 1 |
| Chang, JH | 1 |
| Kuo, SC | 1 |
| Lee, FY | 1 |
| Teng, CM | 1 |
| Garber, K | 1 |
7 reviews available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Benign Neoplasms
| Article | Year |
|---|---|
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Hypo | 2012 |
HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Anthracyclines; Biphenyl Compounds; | 2016 |
HIF-1alpha and cancer therapy.
Topics: Animals; Cell Hypoxia; Histone Deacetylase Inhibitors; Humans; Hypoxia-Inducible Factor 1, alpha Sub | 2010 |
Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Ce | 2011 |
Versatile pharmacological actions of YC-1: anti-platelet to anticancer.
Topics: Animals; Antineoplastic Agents; Cyclic GMP; Guanylate Cyclase; Humans; Hypoxia-Inducible Factor 1, a | 2004 |
New anticancer strategies targeting HIF-1.
Topics: Adaptation, Physiological; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA-Bind | 2004 |
[Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy].
Topics: Animals; Cell Hypoxia; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Humans; Hypoxia-Induc | 2005 |
12 other studies available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hypoxi | 2007 |
Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors.
Topics: Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Drug Design; Humans; Hypoxia-Inducible Factor | 2015 |
Promoting antitumor efficacy by suppressing hypoxia via nano self-assembly of two irinotecan-based dual drug conjugates having a HIF-1α inhibitor.
Topics: A549 Cells; Animals; Antineoplastic Agents; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indaz | 2019 |
YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Cell Hypoxia; Cell Line, Tumor; Cell Survival; | 2020 |
A novel individual-cell-based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin-related delivery in avascular regions.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Diben | 2017 |
Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.
Topics: Animals; Cell Hypoxia; Furans; HeLa Cells; Humans; Hypoxia-Inducible Factor 1; Indazoles; Mice; Mice | 2009 |
YC-1 rescues cancer cachexia by affecting lipolysis and adipogenesis.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Antineoplastic Agents; Cachexia; Enzyme Activators; | 2011 |
Is HIF-1 alpha a valid therapeutic target?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Basic Helix- | 2003 |
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell | 2003 |
YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Blotting, Western; Cell Movement; Cell Prolif | 2005 |
New drugs target hypoxia response in tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drugs, Inve | 2005 |